Eli Lilly and Company

Potential blockbuster arthritis drug delayedCiting safety concerns, FDA delayed approval of a new blockbuster drug to treat rheumatoid arthritis.
New diabetes drug enters competitive marketIn a major new entry in the diabetes market, FDA just approved linagliptin and metformin hydrochloride extended-release tablets (Jentadueto XR, Boehringer Ingelheim and Eli Lilly and Company) to treat type 2 diabetes.